Condition: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) · Sponsor: Rocket Pharmaceuticals Inc.
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
This description comes directly from the study's public registry record.
Clinical Information · 646-627-0033 · clinicaltrials@rocketpharma.com
Always discuss trial participation with your own doctor first.
| University of California, San Diego | La Jolla, California, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Withdrawn |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05885412